相关实验视频

Updated: Jun 17, 2025

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

SPH7854,一种肠局限的RORγt抗剂,可以改善TNBS诱导的实验性大肠炎在老鼠中

Zhijun Xiang¹, Bingbin Zhang¹, Shuangyi Cao¹

¹Central Research Institute, National Key Laboratory of Innovative Immunotherapy, Shanghai Pharmaceuticals Holding Co., Ltd., Shanghai 201203, PR China.

International immunopharmacology

|August 12, 2024

概括

一种新的肠局限RORγt抗剂SPH7854显示出治疗炎症性肠病 (IBD) 的前景. 这种化合物在临床前模型中有效降低了炎症,没有系统性副作用,提供了更安全的治疗方法.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
胃肠病学胃肠病学

背景情况:

与网红酸相关的孤儿核受体马t (RORγt) 是炎症性肠病 (IBD) 治疗的关键标.
系统性RORγt抑制会导致诸如胸腺淋巴瘤和肝脏功能障碍等不良影响.
开发肠局限的RORγt抗剂提供了一个更安全,更有效的IBD治疗策略.

研究的目的:

发现和描述SPH7854,一种新的肠道有限的RORγt对手.
在IBD的临床前模型中评估SPH7854的疗效.
评估SPH7854的安全概况,重点关注肠道受限活动.

主要方法:

在实验室中评估SPH7854对小鼠和人类初级细胞中的T辅助1 (Th1),Th17和调节性T (Treg) 细胞分化的影响.
药物动力学研究,以确定SPH7854在小鼠口服后的肠道有限分布.
评估SPH7854在三二硫酸 (TNBS) 诱导的大肠炎的小鼠模型中的治疗效果.

主要成果:

根据剂量,SPH7854抑制了IL-17A的分泌,抑制了Th17细胞的分化,同时促进了Treg细胞的分化.
药理动力学研究证实了SPH7854的肠道受限性质,具有较低的全身生物可用性.
口服SPH7854显著缓解了TNBS诱导的大肠炎症状,并减少了老鼠结肠中的炎症标志物.

结论:

SPH7854是一种强效和选择性的肠局限RORγt抗剂.
用肠道受限抗剂向RORγt是IBD的一种有前途的治疗策略.
SPH7854证明了安全有效的IBD治疗的潜力,降低了全身毒性.

关键词:

大肠炎是什么意思肠道有限的肠道有限.IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD 罗尔特的时间.Th17 这是一个很好的方法.这就是Treg Treg.

更多相关视频

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...